Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication March 10, 2011
- Accepted for publication May 18, 2011
- Published online November 1, 2011.
Article Versions
- previous version (October 7, 2011 - 05:37).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2011 by Society of Nuclear Medicine
Author Information
- Josef J. Fox*,1,
- Estelle Autran-Blanc*,2,
- Michael J. Morris3,
- Somali Gavane1,
- Sadek Nehmeh4,
- André Van Nuffel5,
- Mithat Gönen6,
- Heiko Schöder1,
- John L. Humm5,
- Howard I. Scher3 and
- Steven M. Larson1
- 1Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
- 2Department of Nuclear Medicine, Cochin Hospital, Paris, France
- 3Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
- 4Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York
- 5General Electric Healthcare, Brussels, Belgium; and
- 6Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
- For correspondence or reprints contact: Josef J. Fox, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. E-mail: foxj{at}mskcc.org
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- 18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients
- Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging
- Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma
- Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
- 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- Measuring Oncogenic Signaling Pathways in Cancer with PET: An Emerging Paradigm from Studies in Castration-Resistant Prostate Cancer